Search DIAN Tissue Requests
In order to avoid the situation where two investigators study the same research question, please search our database to determine if your topic has already been studied. If you find that your topic or a related topic has already been submitted, you may wish to contact the investigator to inquire about his/her findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID # (e.g. DIAN-T1004), the full request has been submitted and is either approved, disapproved or in process.
Displaying 11 - 20 of 55
AD pathology in advanced cellular models
Generation of iPSCs from AD patient fibroblasts
Differentiation of AD iPSCs into neurons
Analysis of cellular networks dysfunction
Leptin and metabolic signaling in autosomal dominant Alzheimer’s disease
To determine if alterations in levels of plasma leptin and related metabolic markers are evident in cognitively normal subjects with autosomal dominant Alzheimer’s disease
To determine if alterations in plasma leptin levels and related metabolic markers correlate with changes in Alzheimer’s disease biomarkers in subjects with autosomal dominant Alzheimer’s disease
To determine if levels of plasma leptin and related metabolic markers correlate with worsening Alzheimer’s disease biomarkers and progression of cognitive decline over time (age) in subjects with autosomal dominant Alzheimer’s disease
Steve Wagner, Ph.D.
Preclinical validation of target engagement for a potent disease modifying therapeutic for AD in dominantly inherited EOFAD patient induced human neurons
Demonstrate target engagement against human neurons harboring EOFAD mutations
Evaluation of the effects of GSMs in hiPSC in-vitro systems on downstream AD pathways
DIAN-ADNI comparison study
In LOAD and ADAD determine whether both groups demonstrate initial cerebral amyloidosis that is followed by the development of neurodegeneration prior to onset of AD symptoms
Characterize similarities and any differences in AD phenotypes between LOAD and ADAD
In both LOAD and ADAD, determine whether there is a pattern of disease progression that is marked by intra-individual global cognitive and functional decline that culminates in death
Examine the contribution of age to the dementing process.
Genetic architecture of CSF biomarker levels in ADAD
To identify genetic variants and genes associated with CSF biomaker levels in DIAN
To determine the overlap in the genetic architecture of late-onset sporadic AD with ADAD
To identify protective and modifiers variants for AD
Characterization of γ-Secretase in fibroblasts derived from FAD patients harboring PSEN1or PSEN2 mutations
Determine in vitro γ-secretase activity for Aβ40 and Aβ42 production using fibroblast cell membranes
Characterize the γ-secretase complexes in fibroblast cell membranes
Examine the sensitivity of various modulators and inhibitors to γ-secretase in fibroblast cell membranes
Comprehensive CSF tau profiling in DIAN using a novel mass spectrometry
Determine stage of the disease where additional p-tau isoforms (particularly p-tau Thr 217) begin to differ between MC and NC based on EYO and Aβ status, and compare this to the currently used immunoassay measures of tau and p-tau181.
Determine longitudinal change (quantitative change / mean and SD) of the various p-tau isoforms identified as it relates to disease stage and how this compares to the currently used immunoassay measures of tau and p-tau181.
Assess the association between baseline and longitudinal CSF MS p-tau isoforms and other measures of disease (neuroimaging- FDG �PET, MRI volumetrics and tau �PET; clinical- CDR, cognition).
Compare the comprehensive CSF tau profile identified in DIAN with that completed and underway in sAD at Washington University by Drs. Barth�lemy and Bateman.
Neuropathological findings of brains of persons with familial AD (FAD) due to the A431E PSEN1 mutation
To thoroughly characterize and describe the neuropathological findings of 11 brains of persons with familial AD (FAD) due to the A431E PSEN1 mutation.
To correlate pathological findings with clinical findings in these patients.
To explain specific clinical and imaging features of the A431E mutation by quantifying aspects of the neuropathology.
Assessment of CSF YKL-40, VILIP-1, and calbindin as diagnostic and prognostic markers
Examine the utility of CSF VILIP-1, YKL-40, and calbindin D28K (alone or in combination with CSF tau, p-tau181, and A?42) in the identification of mutation carrier status in family members of individuals with familial AD compared to non-mutation carrier status.
Investigate whether CSF levels of VILIP-1, YKL-40, and calbindin D28K (alone or in combination with CSF tau, p-tau181, and A?42) can predict symptomatic onset over the study follow-up period.
Determine whether CSF levels of VILIP-1, YKL-40, and calbindin D28K correlate with other CSF and imaging markers of preclinical AD pathology such CSF tau, p-tau181, A?42, and amyloid load on PET-PIB in familial AD.
Prof. Ralph Martins
Investigating blood and CSF lipid biomarkers in autosomal dominantly inherited Alzheimer's disease.
Identify early modifications in plasma, CSF and platelet lipid profiles of DIAN participants which may reveal critical information about the pathobiological cascade that culminates in symptomatic disease.
Demonstrate any correlation that may exist across the two major macromolecule subclasses in the blood and CSF, i.e. lipids and selected proteins (Aβ, ApoE, phospho and total tau) and also contribute to a panel of biomarkers to detect AD through a blood test.
Correlate the DIAN lipid profile with brain imaging data obtained from MRI, FDG-PET and PiB-PET scans and determine whether there exists a link between biochemical alterations occurring in the periphery and brain.